Dr. Erin Burnham, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Kathleen Baker Moore, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Richard Davis, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Deborah Vogel, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. James Brent Sholar, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Patrick Grimsley, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Jennifer Larson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. John D Elliott, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 |
Dr. Johnlukas Butler Webb, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-1111 Fax: 440-627-2170 |
Dr. Matthew J Marion, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1700 E 19th St, The Dalles, OR 97058 Phone: 541-296-7220 |
Paul T Armerding, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1620 E 12th St, The Dalles, OR 97058 Phone: 541-296-9151 Fax: 541-296-9156 |
News Archive
EpiCept Corporation announced today the publication of a new meta-analysis which concluded that interleukin-2 (IL-2) monotherapy is not effective as a maintenance therapy for acute myeloid leukemia (AML) patients in first complete remission. These results were published in the July 7, 2011 edition of Blood, a leading scientific journal in hematology.
Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.
Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
Helicos BioSciences Corporation announced today that, as previously disclosed, it has posted a presentation on its website regarding the advantages of Helicos' single molecule sequencing technology in clinical diagnostics.
› Verified 8 days ago